| Patent Number |
Title Of Patent |
Date Issued |
| 6387373 |
Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
May 14, 2002 |
| The present invention features an adjuvanted vaccine, and methods for preparing an adjuvanted vaccine, preferably for immunizing against influenza, where the adjuvant is a lipid vesicle, and preferably is a nonphospholipid, paucilamellar lipid vesicle. The antigen may be encapsulated |
| 6034073 |
Solvent detergent emulsions having antiviral activity |
March 7, 2000 |
| Methods and pharmaceutical compositions for inactivating an envelope virus using an oil-in-water emulsion including an oil, a surfactant, and an organic phosphate-based solvent are disclosed. These methods can be used to inactivate a wide variety of envelope viruses, such as HIV. |
| 6015832 |
Methods of inactivating bacteria including bacterial spores |
January 18, 2000 |
| Methods for inactivating bacteria including bacterial spores using an oil-in-water emulsion are provided. The oil-in-water emulsion comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of bacteria such as Bacillus. |
| 5961975 |
Type I surface antigen associated with staphylococcus epidermidis |
October 5, 1999 |
| A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and |
| 5866140 |
Type I surface antigen associated with staphylococcus epidermidis |
February 2, 1999 |
| A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and |
| 5795582 |
Adjuvant properties of poly (amidoamine) dendrimers |
August 18, 1998 |
| A new method of adjuvanting a variety of materials has been developed. Starburst dendrimers, primarily poly(amidoamine) starburst dendrimers, can be used as an adjuvant for Influenza antigen and similar materials. Mid-Generation dendrimers are preferred and yield high antibody titer |
| 5730989 |
Oral vaccine against gram negative bacterial infection |
March 24, 1998 |
| The present invention concerns an oral preparation useful as an immunizing agent or vaccine against gram negative bacterial infection. This oral preparation can also be used as a treatment for those infected with gam negative bacteria. The preparations can be used against any gram negati |
| 5700679 |
Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity |
December 23, 1997 |
| A novel formulation having anti-viral and spermicidal properties has been developed. The formulation contains lipid vesicles having an outer bilayer formed of a non-ionic amphiphile, a surfactant such as having spermicidal and/or anti-viral activity, an oil and a sterol. The selection of |
| 5662957 |
Oil containing lipid vesicles with marine applications |
September 2, 1997 |
| Disclosed is a new class of lipid vesicles, liposoils, which have high oil content, low water content, and protein. The liposoils are made using a combination of a surfactant and either dried egg yolk or dried whole egg as the wall material, oil, and an aqueous diluent. Unlike most lipid |
| 5629021 |
Micellar nanoparticles |
May 13, 1997 |
| The present invention relates to micellar nanoparticles and methods of their production. Micellar nanoparticles are made by hydrating a mixture of an oil, a stabilizer/surfactant, and an alcoholic initiator with an aqueous solution. These micellar nanoparticles are normally less than 100 |
| 5626844 |
Monoclonal antibody against ricin A chain |
May 6, 1997 |
| Monoclonal antibodies against the A chain of ricin have been found to be ective in protecting mammals from morbidity arising from exposure to ricin toxin. The neutralizing action of the antibodies does not appear to be mediated by complement or by immunoprecipitation. The antibodies of |
| 5618840 |
Antibacterial oil-in-water emulsions |
April 8, 1997 |
| An antibacterial oil-in-water emulsion for inhibiting the growth of Helicobacter pylori is disclosed. The oil-in-water emulsion of the invention comprises droplets of an oily discontinuous phase dispersed in a continuous phase. The oily discontinuous phase contains an oil carrier and |
| 5549901 |
Antimicrobial oil-in-water emulsions |
August 27, 1996 |
| An antimicrobial lipid-containing oil-in-water emulsion comprising an agent selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary lipid and a cationic halogen-containing compound having a C.sub.12 -C |
| 5547677 |
Antimicrobial oil-in-water emulsions |
August 20, 1996 |
| An antimicrobial lipid-containing oil-in-water emulsion comprising an agent selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary lipid and a cationic halogen-containing compound having a C.sub.12 -C |
| 4824666 |
Method of large scale growth of toxoplasmic microorganisms |
April 25, 1989 |
| A method of producing large scale growth of parasites of the genus Toxoplasma is disclosed which comprises inoculating the microorganisms into a non-adherent human cell line, such as a monocytoid lymphoma cell line, and maintaining the cell line in tissue culture media capable of sup |
